Great link Vogliobene which further highlights Patrys' DEEP...

Great link Vogliobene which further highlights Patrys' DEEP product/discovery pipeline:

1) 200+ IgM AB's they have screened/discovered (i.e., their extensive Antibody library which they haven't even "skimmed the surface of").
2) AB's in late stage pre-clinical development (e.g., PAT LM1)
3) AB's with proven clinical results and in the process of being out licensed (PAT - SC1 for gastric cancer - 10 year + follow-up).
4) ... and now an AB in late stage phase I/IIa trials that has been granted orphan drug status for multiple myeloma (PAT SM6).

5).... and not to forget Patrys "diagnostic programme" (which you have highlighted below) and the potential it brings with the use of nanoparticle medicine using AB's as highly sensitive cancer diagnostic tools - with Patrys lead product PAT- SM6 not just being used to save patients from end-stage myeloma, but also to diagnose very early stage cancer!!

As I have previously mentioned, PAB has all the hallmarks of a great biotech company in the making (i.e., compared to the ECQ's and NEU's that have made big gains on not much more than the skill of their savvy promoters - pitty the pure retail investors that will ultimately be burnt badly!!).